Search Results for: cell therapy companies jersey

Last month we examined emerging biotech Pluristem Therapeutics (PSTI), whose cell therapy treats vascular disease with a novel intramuscular injection that restores patency to damaged arteries. Now, this pioneering technique is showing promise in healing another medical disorder with few alternatives - failed bone marrow transplant (BMT). BMT, a physically demanding ordeal unchanged in procedure since 1968, is performed on 30,000 patients per year at a cost of billions of dollars. Full recover takes up to one year. In the last few months, Pluristem has been making significant progress with a substitute for BMT. In May, a seven-year old girl with aplastic anemia was treated with two intramuscular injections of PLX cells after repeated failed BMTs, and showed rapid recovery in all three blood cell components as Pluristem`s therapy stimulated hematopoietic stem cells. In June, the company`s data at the 2012 Bio International Convention showed positive results of an intramuscular injection of its PLX cells on a range of blood disorders that included primary and secondary bone marrow failure from chemotherapy and radiation therapy in cancer, and acute radiation syndrome (ARS). Now, a second patient with lymphoma has been treated with PLX cells for a failing BMT, in the same … Continue reading →

ALLENDALE, N.J. and WILMINGTON, Del., July 16, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized Contract Development and Manufacturing Organization (CDMO), and SOTIO, LLC, a Delaware limited liability company that is responsible for organizing the U.S. part of a global pivotal Phase 3 clinical trial of SOTIO, LLC's affiliate, SOTIO a.s. ("SOTIO"), announced today that SOTIO, LLC has retained the services of PCT to manufacture clinical products for SOTIO's U.S. part of a global pivotal Phase 3 clinical trial. SOTIO, LLC is an affiliate of a Czech Republic-based biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. SOTIO, LLC will use the services of PCT to transfer and qualify at PCT's Allendale, New Jersey facility, SOTIO's GMP manufacturing process for the U.S. part of a global pivotal Phase 3 clinical trial for SOTIO's autologous dendritic cell vaccine expected to launch in early 2013, subject to FDA approval. As part of this agreement, PCT will complete a technology transfer of SOTIO's current product manufacturing and analytical procedures into PCT's ongoing CDMO operations. PCT will then implement and perform process qualification … Continue reading →

ALLENDALE, N.J. and WILMINGTON, Del., July 16, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized Contract Development and Manufacturing Organization (CDMO), and SOTIO, LLC, a Delaware limited liability company that is responsible for organizing the U.S. part of a global pivotal Phase 3 clinical trial of SOTIO, LLC's affiliate, SOTIO a.s. ("SOTIO"), announced today that SOTIO, LLC has retained the services of PCT to manufacture clinical products for SOTIO's U.S. part of a global pivotal Phase 3 clinical trial. SOTIO, LLC is an affiliate of a Czech Republic-based biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. SOTIO, LLC will use the services of PCT to transfer and qualify at PCT's Allendale, New Jersey facility, SOTIO's GMP manufacturing process for the U.S. part of a global pivotal Phase 3 clinical trial for SOTIO's autologous dendritic cell vaccine expected to launch in early 2013, subject to FDA approval. As part of this agreement, PCT will complete a technology transfer of SOTIO's current product manufacturing and analytical procedures into PCT's ongoing CDMO operations. PCT will then implement and perform process qualification … Continue reading →